- Tonix Pharmaceuticals (TNXP +5.7%) says it expects to report results from Phase IIb testing of its TNX-102 SL drug candidate in patients with fibromyalgia during H2 2014.
- TNXP says it began enrollment in the BESTFIT trial last September which was expected to monitor ~120 patients split equally between groups receiving either TNX-102 SL or placebo, measuring changes in pain intensity.
- TNXP also says it expects to begin a trial of TNX-102 SL as a potential treatment for post-traumatic stress disorder and tension-type headache during Q3 and Q4, respectively.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs